Orion and Abbott still in Simdax trial talks
Finnish drugmaker Orion and US health care major Abbott Laboratories say they are in ongoing talks regarding a possible additional Phase III trial of the heart failure drug Simdax (levosimendan) for intravenous administration. Abbott obtained a worldwide license for the product, excluding Nordic countries, from Orion under a deal established in 1998 (Marketletters passim).
The firms explained that discussions are centered on sharing the costs of the study. Orion said that it is willing to contribute 20.0 million euros ($25.9 million) towards the trial provided that the requirements for the program, to be finalized at an upcoming meeting with the US Food and Drug Administration, are reasonable and acceptable.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze